The European Haemophilia Consortium (EHC) joins other leading patient organisations across Europe in releasing a set of ten key recommendations aimed at improving patient involvement in Joint Clinical Assessments (JCAs) under the EU Health Technology Assessment (HTA) Regulation. This collaborative effort highlights the crucial role of patient experiences and insights in shaping effective healthcare assessments and ensuring that the voices of those directly affected by medical innovations are heard and valued. 

Developed with input from a wide range of patient groups and based on extensive consultation and practical experience, the recommendations are designed to foster a more inclusive, transparent, and patient-centered approach to JCAs. The following ten points summarise their input and we highly encourage they are considered to ensure meaningful and practical patient involvement:

1. Establish a predictable framework for patient involvement in JCAs;

2. Include input from patients, carers and patient organisations;

3. Include patient experience data in JCAs;

4. Streamline patient involvement throughout the process;

5. Provide plain language summaries of technologies;

6. Broaden the pool of patients and specify selection criteria;

7. Provide support to patients;

8. Make JCA and summary reports available in all EU languages;

9. Provide feedback to patients;

10. Adopt a constructive approach to confidentiality and conflict of interest.

They’re also a call to action for the HTA Coordination Group to integrate these practices into the guidelines they develop to enhance the quality and relevance of JCAs. By doing so, they can ensure that assessments reflect the real-world experiences of patients, ultimately leading to more patient-centered healthcare solutions. 

Read the full text of the recommendations here!